Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Commercial

Strategy Explore this Topic

Set Alert for Strategy

Billionaire Mark Cuban Surprises With US Generics Venture

 To increase transparency and affordability, American billionaire and businessman Mark Cuban has launched a US generics venture under the name ‘the Mark Cuban Cost Plus Drugs Company.’ Cuban’s new company is hoping to introduce over 100 drugs by the end of 2021 and build a pharmaceutical factory of its own by 2022. 

Generic Drugs Manufacturing

Germany First As Pfenex And Alvogen Biosimilar Forsteo Is Launched

After launching in the US last year, the teriparatide product developed by Pfenex and Alvogen has been introduced in Europa, via commercialization partner Theramex, beginning with Germany.

Biosimilars Launches

Amneal Eyes Avastin And Praises $120m Biosimilar Development Savings

Amneal is close to a filed pipeline of three biosimilar products in the US, while furthering ambitions in the complex generics and 505(b)(2) space, management told the virtual J.P. Morgan Healthcare Conference.

Biosimilars Generic Drugs
See All

Deals Explore this Topic

Set Alert for Deals

Innovent Expands Internationally With Indonesia Deal

Innovent Biologics has broadened its international reach by striking a licensing deal with PT Etana Biotechnologies in Indonesia for its Byvasda bevacizumab biosimilar.

Biosimilars Deals

Kamada Plans Three More Biosimilar Launches In Israel

Israeli firm Kamada has entered into two agreements for commercialization of three biosimilars in Israel. The company expects to launch the products between 2022 and 2024. 

Biosimilars Deals

Amneal Takes Control Of Kashiv Specialty In $100m+ Deal

Amneal will take a majority stake in Kashiv Specialty Pharmaceuticals after striking a deal worth potentially more than $100m for a 98% stake in the hybrid 505(b)(2) and complex generics specialist.

Deals United States
See All

Manufacturing Explore this Topic

Set Alert for Manufacturing

Billionaire Mark Cuban Surprises With US Generics Venture

 To increase transparency and affordability, American billionaire and businessman Mark Cuban has launched a US generics venture under the name ‘the Mark Cuban Cost Plus Drugs Company.’ Cuban’s new company is hoping to introduce over 100 drugs by the end of 2021 and build a pharmaceutical factory of its own by 2022. 

Generic Drugs Manufacturing

Hikma Stands Firm On Supply As It Scoffs At Latest Amarin Lawsuit

Hikma addressed supply concerns and the latest legal worries for its generic Vascepa product, as well as the recent launch of its long-awaited Advair generic, as management faced the virtual J.P. Morgan Healthcare Conference.

Generic Drugs Strategy

Sanofi Reveals Details Of European API Business

Sanofi has unveiled further details of its European API company, which will be called Euroapi and will be led by Karl Rotthier as CEO.

Manufacturing Ingredients
See All

Sales & Earnings Explore this Topic

Set Alert for Sales & Earnings

After Ups and Downs, Industry Attempts To Normalize In Q3

After seeing a spike in demand due to the coronavirus pandemic in Q1, with a corresponding dip in Q2, the generics industry has largely seen single-digit drops in net revenues in the third quarter of 2020. Meanwhile, the Indian pharma market has seen recovery after facing a challenging coronavirus-induced slump in the first two quarters of 2020.

Coronavirus COVID-19 Generic Drugs

What’s Next? Five Things To Look Out For In January

A third biosimilar to Genentech’s Rituxan is set to hit the US this month, as players begin to publish full-year financial results encompassing a remarkable year.

Generic Drugs Biosimilars

Nichi-Iko’s Operating Profit Slumps More Than 85% As Price Revisions Bite

Japan’s Nichi-Iko saw its bottom line take a hammering in the six months to 30 September, as a number of its products had their prices cut following revisions to the National Health Insurance program.

Sales & Earnings Strategy
See All

People Explore this Topic

Set Alert for People

Haruvi Takes Charge Of Sandoz North America

Novartis has appointed its former global head of M&A, Keren Haruvi, to take over from Carol Lynch as president of Sandoz US and head of North America.

Appointments United States

Who’s Hired? IGBA Names IPA’s Jain As Chair

The International Generic and Biosimilar Medicines Association has named the IPA’s Sudarshan Jain as its new chair. While Celltrion’s chairman has stepped down, Coherus has added two members to its board of directors and Synthon has appointed a new CEO.

Appointments International

Who’s Hired? Pfenex’ Lucy Joins Lykan Bioscience

Pfenex founder and chief business officer Patrick Lucy has left the company to join Lykan Bioscience. Meanwhile, Samsung Biologics has announced the appointment of a new president and CEO, as the Australian generics and biosimilars association appoints a new chair.

Appointments Strategy
See All
UsernamePublicRestriction

Register